The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2024 | PD1 inhibitors in patients with cHL: the potential for combination therapies in earlier lines
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, discusses the use of PD1 inhibitors, such as nivolumab and pembrolizumab, in patients with classical Hodgkin lymphoma (cHL), and highlights the potential for combining these agents with chemotherapy and moving them earlier in the treatment paradigm to increase the number of patients achieving cure. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda, Roche, Beigene, Astra Zeneca, Abbvie, Sobi, Kite / Gilead, BMS, Pfizer, SecuraBio.
